These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 8926680)

  • 1. [Significance of interleukin 10 for acute graft versus host disease in children and adolescents after allogenic bone marrow transplantation].
    Körholz D; Hempel L; Packeisen J; Kunst D; Zintl F; Burdach S
    Klin Padiatr; 1996; 208(4):141-4. PubMed ID: 8926680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Körholz D; Kunst D; Hempel L; Söhngen D; Heyll A; Bönig H; Göbel U; Zintl F; Burdach S
    Bone Marrow Transplant; 1997 Apr; 19(7):691-5. PubMed ID: 9156246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immunodeficiency in patients after bone marrow transplantation.
    Körholz D; Kunst D; Hempel L; Söhngen D; Heyll A; Mauz-Körholz C; Zintl F; Burdach S
    Bone Marrow Transplant; 1996 Dec; 18(6):1123-30. PubMed ID: 8971382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of interleukin-12 in the development of acute graft-versus-host disease in bone marrow transplant patients.
    Yabe M; Yabe H; Hattori K; Shimizu T; Matsumoto M; Morimoto T; Yasuda Y; Inoue H; Kato S; Nishimura T
    Bone Marrow Transplant; 1999 Jul; 24(1):29-34. PubMed ID: 10435731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation.
    MacMillan ML; Radloff GA; Kiffmeyer WR; DeFor TE; Weisdorf DJ; Davies SM
    Transplantation; 2003 Dec; 76(12):1758-62. PubMed ID: 14688528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation.
    Hempel L; Körholz D; Nussbaum P; Bönig H; Burdach S; Zintl F
    Bone Marrow Transplant; 1997 Sep; 20(5):365-8. PubMed ID: 9339750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the severity of graft-versus-host disease from interleukin-10 levels after bone marrow transplantation.
    Takatsuka H; Takemoto Y; Okamoto T; Fujimori Y; Tamura S; Wada H; Okada M; Yamada S; Kanamaru A; Kakishita E
    Bone Marrow Transplant; 1999 Nov; 24(9):1005-7. PubMed ID: 10556960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD.
    Remberger M; Ringden O; Markling L
    Bone Marrow Transplant; 1995 Jan; 15(1):99-104. PubMed ID: 7742764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A possible association between the presence of interleukin-4-secreting cells and a reduction in the risk of acute graft-versus-host disease.
    Takabayashi M; Kanamori H; Takasaki H; Yamaji S; Koharazawa H; Taguchi J; Tomita N; Fujimaki K; Fujisawa S; Maruta A; Ishigatsubo Y
    Exp Hematol; 2005 Feb; 33(2):251-7. PubMed ID: 15676220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Reddy V; Winer AG; Eksioglu E; Meier-Kriesche HU; Schold JD; Wingard JR
    Biol Blood Marrow Transplant; 2005 Dec; 11(12):1014-21. PubMed ID: 16338624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine gene expression by concanavalin A-stimulated peripheral mononuclear cells after bone marrow transplantation: an indicator of immunological abnormality due to chronic graft-versus-host disease.
    Tanaka J; Imamura M; Kasai M; Zhu X; Kobayashi S; Imai K; Hashino S; Higa T; Sakurada K; Miyazaki T
    Bone Marrow Transplant; 1994 Nov; 14(5):695-701. PubMed ID: 7889002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
    Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
    Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of recipient-specific alloreactivity: is GVHD predictable?
    Theobald M; Bunjes D; Nierle T; Arnold R; Heimpel H
    Bone Marrow Transplant; 1993; 12 Suppl 3():S18-23. PubMed ID: 8124251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of low histidine rich glycoprotein plasma levels with the occurrence of acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Mauz-Körholz C; Körholz D; Burdach S
    J Lab Clin Med; 1995 Aug; 126(2):144-50. PubMed ID: 7636387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.